RXRX - Recursion Pharmaceuticals Stock Has 33% Upside According to 1 Wall Street Analyst
2024-03-07 10:28:00 ET
On Monday, Keybanc analyst Scott Schoenhaus revised his price target on Recursion Pharmaceuticals (NASDAQ: RXRX) upward, opining the stock would climb by 33% and hit $16. The call came days after the rare-disease drug developer reported 2023 fourth-quarter earnings, which caused the market to dump its shares to the tune of 13%.
Here's what Shoenhaus could be thinking will catalyze a reversal for this stock.
In January, Recursion made an interesting decision regarding one of the assets it's developing in its fibrotic disease collaboration with Bayer .
For further details see:
Recursion Pharmaceuticals Stock Has 33% Upside, According to 1 Wall Street Analyst